{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T22:43:34Z","timestamp":1786574614072,"version":"build-2736575974"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>SUMOylation, a dynamic regulatory process in post-translational modifications (PTMs) mediated by small ubiquitin-like modifier (SUMO) ligases and deSUMOylases, regulates protein function through reversible lysine conjugation. Emerging evidence has identified tumor-mediated hijacking of SUMOylation in both malignant cells and immune components as a novel immune evasion mechanism. This review represents a comprehensive update on how tumor-intrinsic SUMOylation modulates tumor immunity-related JAK\/STAT, MHC-I, NF-\u03baB, IFN-I\/II pathways and other key proteins to drive its immune evasion, and immune cell-intrinsic SUMOylation in regulating natural killer (NK) and T cell cytotoxicity, dendritic cell (DC) maturation, and macrophage polarization. Tumor immunotherapy is a new potential strategy for cancer, mainly represented by immune checkpoint inhibitions (ICIs), which exhibits poor efficacy in head and neck squamous cell carcinoma (HNSCC), pancreatic ductal adenocarcinoma (PDAC) and other solid tumors. Targeting SUMOylation of tumors presents high potential to synergistically improve the therapeutic effect of ICIs. Preclinical studies have shed light on the therapeutic potential of the combination of SUMOylation inhibitors such as TAK-981 or 2-D08 with ICIs, thus significantly improving tumor prognosis. As current phase I trials suggest dose-dependent toxicity of TAK-981, there is a need for targeted delivery systems; AI-assisted screening of novel SUMOylation inhibitors (SUMOi) which are FDA approved serves as another potential approach; besides, antibodies against these pivotal SUMOylated molecules in tumors could be conjugated with SUMOi to restore the activity of specific proteins in tumor microenvironment. In all, our review proposes that current or other novel strategies for SUMOylation inhibition stands as a promising adjuvant to immunotherapy for tumor management, thereby potentially contributing to the favorable prognosis of cancer patients.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1654167","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T04:12:39Z","timestamp":1759119159000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Unraveling the critical role of SUMOylation in the governing of tumor immunity"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiangfei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cell.2018.11.046","article-title":"Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding","volume":"176","author":"Gkountela","year":"2019","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ccell.2017.10.001","article-title":"Organelle specific O-glycosylation drives MMP14 activation, tumor growth, and metastasis","volume":"32","author":"Nguyen","year":"2017","journal-title":"Cancer Cell"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1016\/j.cell.2023.07.013","article-title":"Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation","volume":"186","author":"Geffen","year":"2023","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"6840","DOI":"10.1038\/s41467-022-34529-6","article-title":"pTINCR microprotein promotes epithelial differentiation and suppresses tumor growth through CDC42 SUMOylation and activation","volume":"13","author":"Boix","year":"2022","journal-title":"Nat Commun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M009476200","article-title":"SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting","volume":"276","author":"Rodriguez","year":"2001","journal-title":"J Biol Chem"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2016.143","article-title":"SUMO and the robustness of cancer","volume":"17","author":"Seeler","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00025.2019","article-title":"SUMO: from bench to bedside","volume":"100","author":"Chang","year":"2020","journal-title":"Physiol Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI152383","article-title":"Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer","volume":"132","author":"Demel","year":"2022","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.1038\/s41467-022-32920-x","article-title":"Crosstalk between SUMOylation and ubiquitylation controls DNA end resection by maintaining MRE11 homeostasis on chromatin","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat Commun"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2015.09.006","article-title":"SUMOylation-mediated regulation of cell cycle progression and cancer","volume":"40","author":"Eifler","year":"2015","journal-title":"Trends Biochem Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-022-00500-y","article-title":"Signaling mechanisms and cellular functions of SUMO","volume":"23","author":"Vertegaal","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-313264","article-title":"SENP1 promotes hypoxia-induced cancer stemness by HIF-1\u03b1 deSUMOylation and SENP1\/HIF-1\u03b1 positive feedback loop","volume":"66","author":"Cui","year":"2017","journal-title":"Gut"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2016.124","article-title":"SUMOylation and SENP3 regulate STAT3 activation in head and neck cancer","volume":"35","author":"Zhou","year":"2016","journal-title":"Oncogene"},{"key":"B14","article-title":"\u03b2-catenin SUMOylation is involved in the dysregulated proliferation of myeloma cells","volume":"5","author":"Huang","year":"2014","journal-title":"Am J Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41419-021-04127-3","article-title":"NSUN2 modified by SUMO-2\/3 promotes gastric cancer progression and regulates mRNA m5C methylation","volume":"12","author":"Hu","year":"2021","journal-title":"Cell Death Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.301523","article-title":"Overexpression of SKI oncoprotein leads to p53 degradation through regulation of MDM2 protein sumoylation","volume":"287","author":"Ding","year":"2012","journal-title":"J Biol Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/387296a0","article-title":"Mdm2 promotes the rapid degradation of p53","volume":"387","author":"Haupt","year":"1997","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"DhatChinamoorthy","year":"2021","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12943-023-01885-w","article-title":"Exploiting innate immunity for cancer immunotherapy","volume":"22","author":"Yi","year":"2023","journal-title":"Mol Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01316-8","article-title":"The cancer metabolic reprogramming and immune response","volume":"20","author":"Xia","year":"2021","journal-title":"Mol Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01813-y","article-title":"Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma","volume":"22","author":"Gautam","year":"2023","journal-title":"Mol Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02912-2","article-title":"Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway","volume":"43","author":"Luo","year":"2024","journal-title":"Oncogene"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1500035","article-title":"Small ubiquitin-like modifier alters IFN response","volume":"195","author":"Maarifi","year":"2015","journal-title":"J Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41419-022-04622-1","article-title":"SUMOylation of PDPK1 Is required to maintain glycolysis-dependent CD4 T-cell homeostasis","volume":"13","author":"Sun","year":"2022","journal-title":"Cell Death Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3497","article-title":"SUMO-specific protease 1 is critical for myeloid-derived suppressor cell development and function","volume":"79","author":"Huang","year":"2019","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1038\/s41467-018-05676-6","article-title":"SENP3 maintains the stability and function of regulatory T cells via BACH2 deSUMOylation","volume":"9","author":"Yu","year":"2018","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-025-01155-4","article-title":"Immune regulation by the SUMO family","volume":"25","author":"Tharuka","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.3114","article-title":"A new vertebrate SUMO enzyme family reveals insights into SUMO-chain assembly","volume":"22","author":"Eisenhardt","year":"2015","journal-title":"Nat Struct Mol Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.bbamcr.2013.08.022","article-title":"SUMO-targeted ubiquitin ligases","volume":"1843","author":"Sriramachandran","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.9.6252","article-title":"Functional heterogeneity of small ubiquitin-related protein modifiers SUMO-1 versus SUMO-2\/3","volume":"275","author":"Saitoh","year":"2000","journal-title":"J Biol Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2020.09.002","article-title":"A chain of events: regulating target proteins by SUMO polymers","volume":"46","author":"Jansen","year":"2021","journal-title":"Trends Biochem Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00091.2016","article-title":"Ubiquitin-dependent and independent roles of SUMO in proteostasis","volume":"311","author":"Liebelt","year":"2016","journal-title":"Am J Physiol Cell Physiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5344.1803","article-title":"Specific inhibition of Stat3 signal transduction by PIAS3","volume":"278","author":"Chung","year":"1997","journal-title":"Science"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.18.10626","article-title":"Inhibition of Stat1-mediated gene activation by PIAS1","volume":"95","author":"Liu","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1101\/gad.955501","article-title":"A new RING for SUMO: wrestling transcriptional responses into nuclear bodies with PIAS family E3 SUMO ligases","volume":"15","author":"Jackson","year":"2001","journal-title":"Genes Dev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02392","article-title":"(PIAS) negatively regulates the JAK\/STAT pathway by inhibiting STAT phosphorylation and translocation","volume":"9","author":"Niu","year":"2018","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.cytogfr.2016.04.003","article-title":"The implication of SUMO in intrinsic and innate immunity","volume":"29","author":"Hannoun","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800327","article-title":"Tumor Suppressor p14ARF Enhances IFN-\u03b3-Activated Immune Response by Inhibiting PIAS1 via SUMOylation","volume":"201","author":"Alagu","year":"2018","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12943-024-02124-6","article-title":"Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1","volume":"23","author":"Zang","year":"2024","journal-title":"Mol Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"B42","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumor-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba7791","article-title":"A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models","volume":"13","author":"Lightcap","year":"2021","journal-title":"Sci Transl Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell"},{"key":"B45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.05.015","article-title":"PIAS1 promotes lymphomagenesis through MYC upregulation","volume":"15","author":"Rabellino","year":"2016","journal-title":"Cell Rep"},{"key":"B47","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40164-024-00563-x","article-title":"Comprehensive antitumor immune response boosted by dual inhibition of SUMOylation and MEK in MYC-expressing KRAS-mutant cancers","volume":"13","author":"Kotani","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2011.04.040","article-title":"Co-repressor activity of scaffold attachment factor B1 requires sumoylation","volume":"408","author":"Garee","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abk0957","article-title":"BATF epigenetically and transcriptionally controls the activation program of regulatory T cells in human tumors","volume":"7","author":"Itahashi","year":"2022","journal-title":"Sci Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0840-4","article-title":"Promotion of tumor-associated macrophages infiltration by elevated neddylation pathway via NF-\u03baB-CCL2 signaling in lung cancer","volume":"38","author":"Zhou","year":"2019","journal-title":"Oncogene"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.cell.2019.07.044","article-title":"Systematic immunotherapy target discovery using genome-scale in vivo CRISPR screens in CD8 T cells","volume":"178","author":"Dong","year":"2019","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.108.192286","article-title":"The orphan nuclear receptor Nur77 suppresses endothelial cell activation through induction of IkappaBalpha expression","volume":"104","author":"You","year":"2009","journal-title":"Circ Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.29","article-title":"SUMO-triggered ubiquitination of NR4A1 controls macrophage cell death","volume":"24","author":"Zhang","year":"2017","journal-title":"Cell Death Differ"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080470","article-title":"SUMOylation is required for optimal TRAF3 signaling capacity","volume":"8","author":"Miliara","year":"2013","journal-title":"PloS One"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1458","article-title":"PIASy mediates NEMO sumoylation and NF-kappaB activation in response to genotoxic stress","volume":"8","author":"Mabb","year":"2006","journal-title":"Nat Cell Biol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.07.044","article-title":"RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia","volume":"131","author":"Carbia-Nagashima","year":"2007","journal-title":"Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30917","article-title":"Mesencephalic astrocyte-derived neurotrophic factor inhibits liver cancer through small ubiquitin-related modifier (SUMO)ylation-related suppression of NF-\u03baB\/snail signaling pathway and epithelial-mesenchymal transition","volume":"71","author":"Liu","year":"2020","journal-title":"Hepatology"},{"key":"B58","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13045-020-00913-2","article-title":"CD155 immunoregulation as a target for natural killer cell immunotherapy in glioblastoma","volume":"13","author":"Lupo","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"10445","DOI":"10.1038\/s41598-017-10403-0","article-title":"Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells","volume":"7","author":"Zitti","year":"2017","journal-title":"Sci Rep"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216988","article-title":"Loss of RBM45 inhibits breast cancer progression by reducing the SUMOylation of IRF7 to promote IFNB1 transcription","volume":"596","author":"Lv","year":"2024","journal-title":"Cancer Lett"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-024-01437-9IF","article-title":"SENP3 inhibition suppresses hepatocellular carcinoma progression and improves the efficacy of anti-PD-1 immunotherapy","volume":"32","author":"Wang","year":"2025","journal-title":"Cell Death Differ"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.abq3362","article-title":"SUMOylated IL-33 in the nucleus stabilizes the transcription factor IRF1 in hepatocellular carcinoma cells to promote immune escape","volume":"16","author":"Wang","year":"2023","journal-title":"Sci Signal"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-324834","article-title":"Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model","volume":"71","author":"Kumar","year":"2022","journal-title":"Gut"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1172\/JCI158352","article-title":"UBC9 deficiency enhances immunostimulatory macrophage activation and subsequent antitumor T cell response in prostate cancer","volume":"133","author":"Xiao","year":"2023","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189260","article-title":"SENP3: cancers and diseases","volume":"1880","author":"Chen","year":"2025","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2021.1984656","article-title":"Full-coverage regulations of autophagy by ROS: from induction to maturation","volume":"18","author":"Zhou","year":"2022","journal-title":"Autophagy"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3892\/or.2013.2318","article-title":"Overexpression of SENP3 in oral squamous cell carcinoma and its association with differentiation","volume":"29","author":"Sun","year":"2013","journal-title":"Oncol Rep"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12967","article-title":"SENP3 loss promotes M2 macrophage polarization and breast cancer progression","volume":"16","author":"Xiao","year":"2022","journal-title":"Mol Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.7150\/thno.95748","article-title":"CBX4 suppresses CD8+ T cell antitumor immunity by reprogramming glycolytic metabolism","volume":"14","author":"Wang","year":"2024","journal-title":"Theranostics"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202201409","article-title":"Genetic disruption of KLF1 K74 SUMOylation in hematopoietic system promotes healthy longevity in mice","volume":"9","author":"Shyu","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1172\/JCI155224","article-title":"SENP7 senses oxidative stress to sustain metabolic fitness and antitumor functions of CD8+ T cells","volume":"132","author":"Wu","year":"2022","journal-title":"J Clin Invest"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.7.4338","article-title":"Activation of dendritic cells via inhibition of Jak2\/STAT3 signaling","volume":"175","author":"Nefedova","year":"2005","journal-title":"J Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nm1325","article-title":"Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity","volume":"11","author":"Kortylewski","year":"2005","journal-title":"Nat Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1172\/JCI176586","article-title":"Autocrine VEGF-B signaling maintains lipid synthesis and mitochondrial fitness to support T cell immune responses","volume":"134","author":"He","year":"2024","journal-title":"J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.127","article-title":"RACK1, a versatile hub in cancer","volume":"34","author":"Li","year":"2015","journal-title":"Oncogene"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16589","article-title":"SENP1-KLF4 signaling regulates LPS -induced macrophage M1 polarization","volume":"290","author":"Wang","year":"2023","journal-title":"FEBS J"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.624112","article-title":"PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action","volume":"12","author":"Hernandez-Quiles","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028423","article-title":"The interferon (IFN) class of cytokines and the IFN regulatory factor (IRF) transcription factor family","volume":"10","author":"Negishi","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1172\/JCI45444","article-title":"Kr\u00fcppel-like factor 4 regulates macrophage polarization","volume":"121","author":"Liao","year":"2011","journal-title":"J Clin Invest"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.066431","article-title":"SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells","volume":"285","author":"Hammerich-Hille","year":"2010","journal-title":"J Biol Chem"},{"key":"B82","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.semcancer.2019.02.001","article-title":"Leslie NR Mechanisms of PTEN loss in cancer: It\u2019s all about diversity","volume":"59","author":"\u00c1lvarez-Garcia","year":"2019","journal-title":"Semin Cancer Biol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2009.210","article-title":"SENP3 is responsible for HIF-1 transactivation under mild oxidative stress via p300 de-SUMOylation","volume":"28","author":"Huang","year":"2009","journal-title":"EMBO J"},{"key":"B84","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.molcel.2020.12.024","article-title":"SENP3 senses oxidative stress to facilitate STING-dependent dendritic cell antitumor function","volume":"81","author":"Hu","year":"2021","journal-title":"Mol Cell"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2012.141","article-title":"Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells","volume":"20","author":"Liu","year":"2013","journal-title":"Cell Death Differ"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103756","article-title":"Therapeutic targeting of \u201cundruggable\u201d MYC","volume":"75","author":"Llombart","year":"2022","journal-title":"EBioMedicine"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174402","article-title":"Therapeutic potential of targeting the SUMO pathway in cancer","volume":"13","author":"Kukkula","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B88","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.trecan.2020.11.009","article-title":"Targeting SUMO signaling to wrestle cancer","volume":"7","author":"Kroonen","year":"2021","journal-title":"Trends Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-LB318","article-title":"SB-4826, a first-in-class oral, covalent inhibitor of SUMO E1 that induces IFN signaling and inhibits tumor growth as monotherapy and in combination with immune checkpoint blockade","volume":"83","author":"Canon","year":"2023","journal-title":"Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-473","article-title":"Inhibition of SUMOylation reverses T-cell metabolic exhaustion in large B-cell lymphoma","volume":"85","author":"Lownik","year":"2025","journal-title":"Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0572","article-title":"Inhibition of SUMOylation Induces Adaptive Antitumor Immunity against Pancreatic Cancer through Multiple Effects on the Tumor Microenvironment","volume":"23","author":"Erdem","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1007\/s13402-023-00880-z","article-title":"SUMOylation inhibitors activate anti-tumor immunity by reshaping the immune microenvironment in a preclinical model of hepatocellular carcinoma","volume":"47","author":"Wang","year":"2024","journal-title":"Cell Oncol (Dordr)"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014267","article-title":"The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation","volume":"139","author":"Nakamura","year":"2022","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cmet.2022.08.007","article-title":"ATF3 and CH25H regulate effector trogocytosis and anti-tumor activities of endogenous and immunotherapeutic cytotoxic T lymphocytes","volume":"34","author":"Lu","year":"2022","journal-title":"Cell Metab"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008654","article-title":"Targeting epigenetic regulation and post-translational modification with 5-Aza-2\u2019 deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapy","volume":"12","author":"Kroonen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-0827","article-title":"Trackable intratumor microdosing and spatial profiling provide early insights into activity of investigational agents in the intact tumor microenvironment","volume":"29","author":"Derry","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.476","article-title":"First-in-human phase 1\/2 study of the first-in-class sumo-activating enzyme inhibitor tak-981 in patients with advanced or metastatic solid tumors or relapsed\/refractory lymphoma: phase 1 results","volume":"9","author":"Dudek","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(22)01134-0","article-title":"Subasumstat, a first-in-class inhibitor of SUMO-activating enzyme, demonstrates dose-dependent target engagement and SUMOylation inhibition, leading to rapid activation of innate and adaptive immune responses in the dose escalation portion of a phase 1\/2 clinical study","volume":"174","author":"Saggu","year":"2022","journal-title":"Eur J Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1654167\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T04:12:40Z","timestamp":1759119160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1654167\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":98,"alternative-id":["10.3389\/fimmu.2025.1654167"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1654167","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"article-number":"1654167"}}